Evidence map›Paper›PMID 23098299›Full record

ArticleHybridoma (2005)2012

A versatile monoclonal antibody specific to human SERPINB5.

Sonia S Y Teoh, Hong Wang, Gail P Risbridger, James C Whisstock, Phillip I Bird

Abstract read
In one paragraph

Article in Hybridoma (2005), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sonia S Y TeohDepartment of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Victoria, Australia.
Hong Wang
Gail P Risbridger
James C Whisstock
Phillip I Bird
Monash University · AUAustralian Research Council · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maspin (SERPINB5) is a member of the Clade B subgroup of the large superfamily of serine protease inhibitors. It is proposed that maspin is a tumor suppressor; however, its molecular role remains to be elucidated. Here we report the characterization of a mouse monoclonal antibody directed against human maspin. This antibody, 16F7, recognizes maspin in both its native and denatured form, unlike several other commercial antibodies tested in this study. It will be a useful and versatile tool for future analyses of the biological function of maspin.

Indexed as

Antibody SpecificityAnimalsAntibodies, MonoclonalBlotting, WesternCell Line, TumorChlorocebus aethiopsCOS CellsEnzyme-Linked Immunosorbent AssayEscherichia coliGene ExpressionHumansMiceProtein BindingProtein ConformationProtein DenaturationRecombinant ProteinsAntibodies, MonoclonalRecombinant ProteinsSERPIN-B5Serpins

Identifiers

PMID23098299
PMCPMC3482377
OpenAlexW1980420195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.